In recent years, chemodynamic therapy (CDT) has received extensive attention as a novel means of cancer treatment. The CDT agents can exert Fenton and Fenton-like reactions in the acidic tumor microenvironment (TME), converting hydrogen peroxide (HO) into highly toxic hydroxyl radicals (·OH). However, the pH of TME, as an essential factor in the Fenton reaction, does not catalyze the reaction effectively, hindering its efficiency, which poses a significant challenge for the future clinical application of CDT. Therefore, this paper reviews various strategies to enhance the antitumor properties of nanomaterials by modulating tumor acidity. Ultimately, the performance of CDT can be further improved by inducing strong oxidative stress to produce sufficient ·OH. In this paper, the various acidification pathways and proton pumps with potential acidification functions are mainly discussed, such as catalytic enzymes, exogenous acids, CAIX, MCT, NHE, NBCn1, etc. The problems, opportunities, and challenges of CDT in the cancer field are also discussed, thereby providing new insights for the design of nanomaterials and laying the foundation for their future clinical applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196673 | PMC |
| http://dx.doi.org/10.2147/IJN.S366187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cadmium Reduces VE-Cadherin Expression in Endothelial Cells Through Activation of the Notch Signaling Pathway.
J Biochem Mol Toxicol
January 2025
Laboratory of Translational Medicine in Microvascular Regulation, Medical Research Center, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital; Shandong Provincial Key Laboratory of Medicine in Microvascular Ageing; Laboratory of Future Industry of Gene Editing in Vascular Endothelial Cells of Universities in Shandong Province, Jinan, China.
Cadmium (Cd) is a toxic heavy metal which induces vascular disorders. Previous studies suggest that Cd in the bloodstream affects vascular endothelial cells (ECs), potentially contributing to vascular-related diseases. However, the molecular mechanisms of effects of Cd on ECs remain poorly understood.
View Article and Find Full Text PDFCurrent Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.
Drug Dev Res
February 2025
South University School of Pharmacy, Savannah, Giorgia, USA.
KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.
View Article and Find Full Text PDFKidney Injury Following Cardiac Surgery: A Review of Our Current Understanding.
Am J Cardiovasc Drugs
January 2025
Pediatric Nephrology, State University of Campinas, São Paulo, Brazil.
Around one-quarter of all patients undergoing cardiac procedures, particularly those on cardiopulmonary bypass, develop cardiac surgery-associated acute kidney injury (CSA-AKI). This complication increases the risk of several serious morbidities and of mortality, representing a significant burden for both patients and the healthcare system. Patients with diminished kidney function before surgery, such as those with chronic kidney disease, are at heightened risk of developing CSA-AKI and have poorer outcomes than patients without preexisting kidney injury who develop CSA-AKI.
View Article and Find Full Text PDFNegative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
CNS Drugs
January 2025
New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.
Article Synopsis
- The negative symptoms of schizophrenia, like lack of emotion and motivation, are hard to treat and significantly impact daily functioning.
- This review highlights current research on treatment options for these symptoms, categorizing them into different types and evaluating various assessment scales.
- Although no treatments are conclusively proven as the best for these symptoms, some off-label and investigational medications show promise, including cariprazine and memantine, and further research is needed to explore new therapeutic possibilities.
Correlation between sarcopenia and hypertrophy of the future liver remnant in patients undergoing portal vein embolization before liver resection.
Br J Radiol
January 2025
Department of Hepatobiliary Surgery, Institute of Liver and Biliary Sciences, New Delhi.
Objectives: To study the correlation between sarcopenia and hypertrophy of the future liver remnant(FLR) in patients undergoing portal vein embolization(PVE) before liver resection, and to assess the outcomes after resection.
Methods: This retrospective study examined patients underwent PVE from May 2012 to May 2023. Demographic, clinical and laboratory features were documented and total liver volumes(TLV) and FLR volumes were measured before and 2-4 weeks after PVE.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!